One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

Peter M.A. Calverley, Stephen Israel Rennard, Harold S. Nelson, Jill P. Karpel, Eduardo H. Abbate, Paul Stryszak, Heribert Staudinger

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Many patients with chronic obstructive pulmonary disease (COPD) are treated with twice daily (BID) inhaled corticosteroids (ICS). This study evaluated whether daily PM mometasone furoate administered via a dry powder inhaler (MF-DPI) was equally effective compared to twice daily dosing.In a 52-week, randomized, double-blind, placebo-controlled study, 911 subjects with moderate-to-severe COPD managed without ICS received MF-DPI 800 μg QD PM, MF-DPI 400 μg BID, or placebo. The change from baseline in postbronchodilator forced expiratory volume in 1 second (FEV1), total COPD symptom scores, and health status as well as the percentage of subjects with a COPD exacerbation were assessed. Adverse events were recorded.Mometasone furoate administered via a dry powder inhaler 800 μg QD PM and 400 μg BID significantly increased postbronchodilator FEV1 from baseline (50 mL and 53 mL, respectively, versus a 19 mL decrease for placebo; P < 0.001). The percentage of subjects exacerbating was significantly lower in the pooled MF-DPI groups than in the placebo group (P = 0.043). Subjects receiving MF-DPI 400 μg BID reported a statistically significant (19%) reduction in COPD symptom scores compared with placebo (P < 0.001). Health status as measured with St. George's Respiratory Questionnaire (SGRQ) improved significantly in all domains (Total, Activity, Impacts, and Symptoms) in the pooled MF-DPI groups versus placebo (P μ 0.031). MF-DPI treatment was well tolerated.Once-daily MF-DPI improved lung function and health status in subjects with moderate-to-severe COPD and was comparable to BID MF-DPI.

Original languageEnglish (US)
Article number73
JournalRespiratory Research
Volume9
DOIs
StatePublished - Nov 13 2008

Fingerprint

Mometasone Furoate
Chronic Obstructive Pulmonary Disease
Placebos
Dry Powder Inhalers
Health Status
Forced Expiratory Volume
Adrenal Cortex Hormones
Therapeutics
Disease Progression

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Calverley, P. M. A., Rennard, S. I., Nelson, H. S., Karpel, J. P., Abbate, E. H., Stryszak, P., & Staudinger, H. (2008). One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research, 9, [73]. https://doi.org/10.1186/1465-9921-9-73

One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. / Calverley, Peter M.A.; Rennard, Stephen Israel; Nelson, Harold S.; Karpel, Jill P.; Abbate, Eduardo H.; Stryszak, Paul; Staudinger, Heribert.

In: Respiratory Research, Vol. 9, 73, 13.11.2008.

Research output: Contribution to journalArticle

Calverley, PMA, Rennard, SI, Nelson, HS, Karpel, JP, Abbate, EH, Stryszak, P & Staudinger, H 2008, 'One-year treatment with mometasone furoate in chronic obstructive pulmonary disease', Respiratory Research, vol. 9, 73. https://doi.org/10.1186/1465-9921-9-73
Calverley PMA, Rennard SI, Nelson HS, Karpel JP, Abbate EH, Stryszak P et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respiratory Research. 2008 Nov 13;9. 73. https://doi.org/10.1186/1465-9921-9-73
Calverley, Peter M.A. ; Rennard, Stephen Israel ; Nelson, Harold S. ; Karpel, Jill P. ; Abbate, Eduardo H. ; Stryszak, Paul ; Staudinger, Heribert. / One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. In: Respiratory Research. 2008 ; Vol. 9.
@article{c44b2a3804fe4a4d8e4050f2d9737f98,
title = "One-year treatment with mometasone furoate in chronic obstructive pulmonary disease",
abstract = "Many patients with chronic obstructive pulmonary disease (COPD) are treated with twice daily (BID) inhaled corticosteroids (ICS). This study evaluated whether daily PM mometasone furoate administered via a dry powder inhaler (MF-DPI) was equally effective compared to twice daily dosing.In a 52-week, randomized, double-blind, placebo-controlled study, 911 subjects with moderate-to-severe COPD managed without ICS received MF-DPI 800 μg QD PM, MF-DPI 400 μg BID, or placebo. The change from baseline in postbronchodilator forced expiratory volume in 1 second (FEV1), total COPD symptom scores, and health status as well as the percentage of subjects with a COPD exacerbation were assessed. Adverse events were recorded.Mometasone furoate administered via a dry powder inhaler 800 μg QD PM and 400 μg BID significantly increased postbronchodilator FEV1 from baseline (50 mL and 53 mL, respectively, versus a 19 mL decrease for placebo; P < 0.001). The percentage of subjects exacerbating was significantly lower in the pooled MF-DPI groups than in the placebo group (P = 0.043). Subjects receiving MF-DPI 400 μg BID reported a statistically significant (19{\%}) reduction in COPD symptom scores compared with placebo (P < 0.001). Health status as measured with St. George's Respiratory Questionnaire (SGRQ) improved significantly in all domains (Total, Activity, Impacts, and Symptoms) in the pooled MF-DPI groups versus placebo (P μ 0.031). MF-DPI treatment was well tolerated.Once-daily MF-DPI improved lung function and health status in subjects with moderate-to-severe COPD and was comparable to BID MF-DPI.",
author = "Calverley, {Peter M.A.} and Rennard, {Stephen Israel} and Nelson, {Harold S.} and Karpel, {Jill P.} and Abbate, {Eduardo H.} and Paul Stryszak and Heribert Staudinger",
year = "2008",
month = "11",
day = "13",
doi = "10.1186/1465-9921-9-73",
language = "English (US)",
volume = "9",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",

}

TY - JOUR

T1 - One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

AU - Calverley, Peter M.A.

AU - Rennard, Stephen Israel

AU - Nelson, Harold S.

AU - Karpel, Jill P.

AU - Abbate, Eduardo H.

AU - Stryszak, Paul

AU - Staudinger, Heribert

PY - 2008/11/13

Y1 - 2008/11/13

N2 - Many patients with chronic obstructive pulmonary disease (COPD) are treated with twice daily (BID) inhaled corticosteroids (ICS). This study evaluated whether daily PM mometasone furoate administered via a dry powder inhaler (MF-DPI) was equally effective compared to twice daily dosing.In a 52-week, randomized, double-blind, placebo-controlled study, 911 subjects with moderate-to-severe COPD managed without ICS received MF-DPI 800 μg QD PM, MF-DPI 400 μg BID, or placebo. The change from baseline in postbronchodilator forced expiratory volume in 1 second (FEV1), total COPD symptom scores, and health status as well as the percentage of subjects with a COPD exacerbation were assessed. Adverse events were recorded.Mometasone furoate administered via a dry powder inhaler 800 μg QD PM and 400 μg BID significantly increased postbronchodilator FEV1 from baseline (50 mL and 53 mL, respectively, versus a 19 mL decrease for placebo; P < 0.001). The percentage of subjects exacerbating was significantly lower in the pooled MF-DPI groups than in the placebo group (P = 0.043). Subjects receiving MF-DPI 400 μg BID reported a statistically significant (19%) reduction in COPD symptom scores compared with placebo (P < 0.001). Health status as measured with St. George's Respiratory Questionnaire (SGRQ) improved significantly in all domains (Total, Activity, Impacts, and Symptoms) in the pooled MF-DPI groups versus placebo (P μ 0.031). MF-DPI treatment was well tolerated.Once-daily MF-DPI improved lung function and health status in subjects with moderate-to-severe COPD and was comparable to BID MF-DPI.

AB - Many patients with chronic obstructive pulmonary disease (COPD) are treated with twice daily (BID) inhaled corticosteroids (ICS). This study evaluated whether daily PM mometasone furoate administered via a dry powder inhaler (MF-DPI) was equally effective compared to twice daily dosing.In a 52-week, randomized, double-blind, placebo-controlled study, 911 subjects with moderate-to-severe COPD managed without ICS received MF-DPI 800 μg QD PM, MF-DPI 400 μg BID, or placebo. The change from baseline in postbronchodilator forced expiratory volume in 1 second (FEV1), total COPD symptom scores, and health status as well as the percentage of subjects with a COPD exacerbation were assessed. Adverse events were recorded.Mometasone furoate administered via a dry powder inhaler 800 μg QD PM and 400 μg BID significantly increased postbronchodilator FEV1 from baseline (50 mL and 53 mL, respectively, versus a 19 mL decrease for placebo; P < 0.001). The percentage of subjects exacerbating was significantly lower in the pooled MF-DPI groups than in the placebo group (P = 0.043). Subjects receiving MF-DPI 400 μg BID reported a statistically significant (19%) reduction in COPD symptom scores compared with placebo (P < 0.001). Health status as measured with St. George's Respiratory Questionnaire (SGRQ) improved significantly in all domains (Total, Activity, Impacts, and Symptoms) in the pooled MF-DPI groups versus placebo (P μ 0.031). MF-DPI treatment was well tolerated.Once-daily MF-DPI improved lung function and health status in subjects with moderate-to-severe COPD and was comparable to BID MF-DPI.

UR - http://www.scopus.com/inward/record.url?scp=63349090227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63349090227&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-9-73

DO - 10.1186/1465-9921-9-73

M3 - Article

VL - 9

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

M1 - 73

ER -